Forma Therapeutics Holdings (Forma Therapeutics Holdings) 3-Year Dividend Growth Rate : 0.00% (As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Forma Therapeutics Holdings 3-Year Dividend Growth Rate?

Forma Therapeutics Holdings's Dividends per Share for the three months ended in Jun. 2022 was $0.00.

The historical rank and industry rank for Forma Therapeutics Holdings's 3-Year Dividend Growth Rate or its related term are showing as below:

FMTX's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Forma Therapeutics Holdings's Dividend Payout Ratio for the three months ended in Jun. 2022 was 0.00. As of today, Forma Therapeutics Holdings's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Forma Therapeutics Holdings's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Forma Therapeutics Holdings's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Forma Therapeutics Holdings's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forma Therapeutics Holdings's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Forma Therapeutics Holdings's 3-Year Dividend Growth Rate falls into.

Forma Therapeutics Holdings 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Forma Therapeutics Holdings (NAS:FMTX) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Forma Therapeutics Holdings's Dividend Payout Ratio for the quarter that ended in Jun. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2022 )	/	EPS without NRI (Q: Jun. 2022 )
	=	0	/	-1.1
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Forma Therapeutics Holdings 3-Year Dividend Growth Rate Related Terms>

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forma Therapeutics Holdings Inc (NAS:FMTX) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 North Beacon Street, Suite 501, Watertown, MA, USA, 02472

Website

https://www.formatherapeutics.com

Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others.

Executives

Agustin Melian	officer: EVP, Research & Development	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Brian Andrew Lesser	officer: SVP, Commercial Officer	C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET SUITE 501 WATERTOWN MA 02472
Mary E. Wadlinger	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Jeannette Potts	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Frank D. Lee	director, officer: President and CEO	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
David N Cook	officer: SVP, Chief Scientific Officer
Patrick F. Kelly	officer: SVP, Chief Medical Officer	C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Todd Shegog	officer: SVP, Chief Financial Officer	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Arturo Md Molina	director	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
John E Bishop	officer: Chief Technology Officer	675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Vickers Selwyn M Md	director	600 NORTH 18TH STREET, BIRMINGHAM AL 35203
Thomas G Wiggans	director
Frederick Wayne A.i.	director	500 W MAIN ST., LOUISVILLE KY 40202
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116